H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aslan Pharmaceuticals Ltd (ASLN) today and set a price target of $12. The company’s shares closed yesterday at $4.76, close to its 52-week low of $4.20.
“Our price target is derived from a market value of the firm at $382M. This valuation includes a discounted cash flow analysis based asset value of $392M for varlitinib and ASLAN003, using a 15% discount rate and 0.5% terminal growth rate and excluding $10M debt.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -16.9% and a 23.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.
Currently, the analyst consensus on Aslan Pharmaceuticals Ltd is a Moderate Buy with an average price target of $12.
The company has a one-year high of $10.44 and a one-year low of $4.20. Currently, Aslan Pharmaceuticals Ltd has an average volume of 8,030.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002.